doi:10.3969/j.issn.1004-583X.2021.02.016

Abstract

CLC Number:

R593.24

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.02.016

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I2/174

References 44

[1]	Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease[J]. Nat Rev Neurosci, 2018,19(11):687-700. doi: 10.1038/s41583-018-0067-3 URL
[2]	Jiang C, Li G, Huang P, et al. The gut microbiota and Alzheimer’s disease[J]. J Alzheimers Dis, 2017,58(1):1-15. doi: 10.3233/JAD-161141 URL
[3]	Cattaneo A, Cattane N, Galluzzi S, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly[J]. Neurobiol Aging, 2017,49:60-68. doi: 10.1016/j.neurobiolaging.2016.08.019 URL
[4]	Zhuang ZQ, Shen LL, Li WW, et al. Gut microbiota is altered in patients with Alzheimer’s disease[J]. J Alzheimers Dis, 2018,63(4):1337-1346. doi: 10.3233/JAD-180176 URL
[5]	Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health[J]. J AOAC Int, 2012,95(1):50-60. pmid: 22468341
[6]	Vijay N, Morris ME. Role of monocarboxylate transporters in drug delivery to the brain[J]. Curr Pharm Des, 2014,20(10):1487-1498. doi: 10.2174/13816128113199990462 URL
[7]	Govindarajan N, Agis-Balboa RC, Walter J, et al. Sodium butyrate improves memory function in an Alzheimer’s disease mouse model when administered at an advanced stage of disease progression[J]. J Alzheimers Dis, 2011,26(1):187-197. doi: 10.3233/JAD-2011-110080 URL
[8]	Bourassa MW, Alim I, Bultman SJ, et al. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health[J]. Neurosci Lett, 2016,625:56-63. doi: 10.1016/j.neulet.2016.02.009 URL
[9]	Erny D, de Angelis ALH, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS[J]. Nat Neurosci, 2015,18(7):965-977. doi: 10.1038/nn.4030 pmid: 90116967293390874
[10]	Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis[J]. J Neuroinflammation, 2014,11:48. doi: 10.1186/1742-2094-11-48 URL
[11]	Zhao Y, Jaber V, Lukiw WJ. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): Detection of lipopolysaccharide (LPS) in AD hippocampus[J]. Front Cell Infect Microbiol, 2017,7:318. doi: 10.3389/fcimb.2017.00318 URL
[12]	Barton SM, Janve VA, McClure R, et al. Lipopolysaccharide induced opening of the blood brain barrier on aging 5XFAD mouse model[J]. J Alzheimers Dis. 2019,67(2), 503-513. doi: 10.3233/JAD-180755 pmid: WOS:000457779300007
[13]	Aziz Q, Doré J, Emmanuel A, et al. Gut microbiota and gastrointestinal health: current concepts and future directions[J]. Neurogastroenterol Motil, 2013,25(1):4-15. doi: 10.1111/nmo.2012.25.issue-1 URL
[14]	Wang MM, Miao D, Cao XP, et al. Innate immune activation in Alzheimer’s disease[J]. Ann Transl Med, 2018,6(10):177. doi: 10.21037/atm URL
[15]	Alexandrov P, Zhai Y, Li W, et al. Lipopolysaccharide-stimulated, NF-kB-, miRNA-146a- and miRNA-155-mediated molecular-genetic communication between the human gastrointestinal tract microbiome and the brain[J]. Folia Neuropathol, 2019,57(3):211-219. doi: 37898 pmid: 31588707
[16]	Iadanza MG, Jackson MP, Hewitt EW, et al. A new era for understanding amyloid structures and disease[J]. Nat Rev Mol Cell Biol, 2018,19(12):755-773. doi: 10.1038/s41580-018-0060-8 URL
[17]	Marques F, Sousa JC, Sousa N, et al. Blood-brain-barriers in aging and in Alzheimer's disease[J]. Mol Neurodegener. 2013,8:38. doi: 10.1186/1750-1326-8-38 URL
[18]	Hill JM, Lukiw WJ. Microbial-generated amyloids and Alzheimer’s disease (AD)[J]. Front Aging Neurosci, 2015,7:9.
[19]	Yu Y, Ye RD. Microglial Aβ receptors in Alzheimer’s disease[J]. Cell Mol Neurobiol, 2015,35(1):71-83. doi: 10.1007/s10571-014-0101-6 URL
[20]	Lukiw WJ, Li W, Bond T, et al. Facilitation of gastrointestinal (GI) tract microbiome-derived lipopolysaccharide (LPS) entry into human neurons by amyloid beta-42 (Aβ42) peptide[J]. Front Cell Neurosci, 2019,13:545. doi: 10.3389/fncel.2019.00545 URL
[21]	Solas M, Puerta E, Ramirez MJ. Treatment options in Alzheimer's disease:the GABA story[J]. Curr Pharm Des, 2015,21(34):4960-4971. doi: 10.2174/1381612821666150914121149 URL
[22]	Maqsood R, Stone TW. The gut-brain axis, BDNF, NMDA and CNS disorders[J]. Neurochem Res, 2016,41(11):2819-2835. doi: 10.1007/s11064-016-2039-1 URL
[23]	Pistollato F, Iglesias RC, Ruiz R, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: A focus on human studies[J]. Pharmacol Res, 2018,131:32-43. doi: 10.1016/j.phrs.2018.03.012 URL
[24]	Akbari E, Asemi Z, Daneshvar Kakhaki R, et al. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease:a randomized, double-blind and controlled trial[J]. Front Aging Neurosci, 2016,8:256.
[25]	Nik Azm SA, Djazayeri A, Safa M, et al. Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1-42) injected rats[J]. Appl Physiol Nutr Metab, 2018,43(7):718-726. doi: 10.1139/apnm-2017-0648 URL
[26]	Chen D, Zhang P, Lin Li, et al. Protective effect of oligosaccharides from Morinda officinalis on beta-amyloid-induced dementia rats[J]. Zhongguo Zhong Yao Za Zhi, 2013,38(9):1306-1309.
[27]	Chen D, Yang X, Yang J, et al. Prebiotic effect of Fructooligosaccharides from Morinda officinalis on Alzheimer’s disease in rodent models by targeting the microbiota-gut-brain axis[J]. Front Aging Neurosci, 2017,9:403. doi: 10.3389/fnagi.2017.00403 URL
[28]	杨玉芳. 当归芍药散对APP/PSN阿尔茨海默病模型小鼠肠道菌群的影响及分子机制[D]. 皖南医学院, 2016.
[29]	杨璐, 李庆华, 许玲, 等. 粪菌移植对阿尔茨海默病小鼠学习记忆能力的影响[J]. 郑州大学学报(医学版), 2017,52(6):702-706.
[30]	Kim M, Kim Y, Choi H, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model[J]. Gut, 2020,69(2):283-294. doi: 10.1136/gutjnl-2018-317431 URL
[31]	Ho L, Ono K, Tsuji M, et al. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms[J]. Expert Rev Neurother, 2018,18(1):83-90. doi: 10.1080/14737175.2018.1400909 URL
[32]	Gu Y, Scarmeas N. Dietary patterns in Alzheimer's disease and cognitive aging[J]. Curr Alzheimer Res. 2011,8(5):510-519. pmid: 21605048
[33]	Nagpal R, Neth BJ, Wang S, et al. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment[J]. EBioMedicine, 2019,47:529-542. doi: 10.1016/j.ebiom.2019.08.032 URL
[34]	Yulug B, Hanoglu L, Ozansoy M, et al. Therapeutic role of rifampicin in Alzheimer’s disease[J]. Psychiatry Clin Neurosci, 2018,72(3):152-159. doi: 10.1111/pcn.2018.72.issue-3 URL
[35]	Budni J, Garcez ML, de Medeiros J, et al. The anti-inflammatory role of minocycline in Alzheimer’s Disease[J]. Curr Alzheimer Res, 2016,13(12):1319-1329. pmid: 27539598
[36]	Wang C, Yu J-T, Miao D, et al. Targeting the mTOR signaling network for Alzheimer’s disease therapy[J]. Mol Neurobiol, 2014,49(1):120-135. doi: 10.1007/s12035-013-8505-8 URL
[37]	Desbonnet L, Clarke G, Traplin A, et al. Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour[J]. Brain Behav Immun, 2015,48:165-173. doi: 10.1016/j.bbi.2015.04.004 URL
[38]	Contaldi F, Capuano F, Fulgione A, et al. Author correction: The hypojournal that helicobacter pylori predisposes to Alzheimer's disease is biologically plausible[J]. Sci Rep, 2018,8(1):6061. doi: 10.1038/s41598-018-23613-x URL
[39]	Kountouras J, Gavalas E, Zavos C, et al. Alzheimer's disease and helicobacter pylori infection: defective immune regulation and apoptosis as proposed common links[J]. Med Hypotheses, 2007,68(2):378-388. pmid: 16979298
[40]	Wang XL, Zeng J, Yang Y, et al. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β[J]. J Alzheimers Dis, 2015,43(1):153-165. doi: 10.3233/JAD-140198 URL
[41]	Cui B, Li K, Gai Z, et al. Chronic noise exposure acts cumulatively to exacerbate Alzheimer’s disease-like amyloid-β pathology and neuroinflammation in the rat hippocampus[J]. Sci Rep, 2015,5:12943. doi: 10.1038/srep12943 URL
[42]	Cui B, Su D, Li W, et al. Effects of chronic noise exposure on the microbiome-gut-brain axis in senescence-accelerated prone mice: implications for Alzheimer’s disease[J]. J Neuroinflammation, 2018,15(1):190. doi: 10.1186/s12974-018-1223-4 URL
[43]	Bharathi, Vasudevaraju P, Govindaraju M, et al. Molecular toxicity of aluminium in relation to neurodegeneration[J]. Indian J Med Res, 2008,128(4):545-556. pmid: 19106446
[44]	Alexandrov PN, Hill JM, Zhao Y, et al. Aluminum-induced generation of lipopolysaccharide (LPS) from the human gastrointestinal (GI)-tract microbiome-resident Bacteroides fragilis[J]. J Inorg Biochem, 2020,203:110886. doi: 10.1016/j.jinorgbio.2019.110886 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 44

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qin Meijie, Tian Maolu, Yang Yuqi, Zha Yan, Yuan Jing. Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review [J]. Clinical Focus, 2022, 37(6): 544-547.
[2]	. [J]. Clinical Focus, 2015, 30(9): 1066-1069.
[3]	Gao Yuan;Meng Qinghua;Liu Haixia;Zhu Yueke. Abnormal liver function as the first symptom of systemic lupus erythematosus: analysis of 15 cases [J]. Clinical Focus, 2015, 30(7): 806-810.
[4]	Li Wenru;Xing Guangqun. Effect of contact system and neutrophil extracellular traps in pathogenesis of lupus nephritis [J]. Clinical Focus, 2015, 30(6): 653-656.
[5]	HUANG Zhi-fang;LI Xin-lun;LI Hong-xia;LUN Li-de. Efficacy and safety of intravenous immunoglobulin in severe systemic lupus erythematosus [J]. Clinical Focus, 2014, 29(11): 1243-1245.
[6]	. [J]. Clinical Focus, 2014, 29(9): 1066-1067.
[7]	LI Hong-bo;ZHANG Jing-kun;WU Chao;WANG Ji;ZHANG Yu-jun;GAO Li-xia. Relationship of high mobility group protein 1,Toll-like receptors 4, vascular endothelial cell adhesion molecule-1 expression in lupus nephritis with dyslipidemia [J]. Clinical Focus, 2014, 29(8): 891-895.
[8]	. [J]. CLINICAL FOCUS, 2014, 29(3): 357-0.
[9]	. [J]. CLINICAL FOCUS, 2013, 28(10): 1179-1181.
[10]	. [J]. CLINICAL FOCUS, 2013, 28(9): 1059-1060.
[11]	WANG Zeng-ling;XING Guang-qun;LI Chun-mei. Level and significance of serum peptidylarginine deiminase type 4 in patients with systemic lupus erythematous [J]. Clinical Focus, 2013, 28(5): 515-518.
[12]	XU Xiao-ling;YU Xuan-hua;LI Yi-nong. Levels and clinical significance of B cell activating factor and interferon-α in systemic lupus erythematosus [J]. Clinical Focus, 2013, 28(5): 522-524532.
[13]	DUAN Ji-hui;JIANG Yan;MU Hong;TANG Zhi-qin;JIANG Jie-chun. Expression of TACI in patients with lupus nephritis [J]. Clinical Focus, 2013, 28(2): 141-143147.
[14]	. [J]. Clinical Focus, 2013, 28(1): 103-104.
[15]	PANG Jie;ZHOU Lei;WANG Kun-kun;CHEN Xian. Factors associated with metabolic syndrome in systemic lupus erythematosus [J]. Clinical Focus, 2012, 27(21): 1844-1846.